Corline Biomedical Q4: Focus on Kardium’s market launch - Redeye

Redeye provides an update following Corline’s Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.

Länk till analysen i sin helhet: https://www.redeye.se/research/1078948/corline-biomedical-q4-focus-on-kardiums-market-launch?utm_source=finwire&utm_medium=RSS